A recent report published by Infinium Global Research on erectile dysfunction drugs market provides an in-depth analysis of segments and sub-segments in the global as well as regional erectile dysfunction drugs market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional erectile dysfunction drugs market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of the global erectile dysfunction drugs market. According to the report, the global erectile dysfunction drugs market is projected to grow at a CAGR of 6.8% over the forecast period of 2018-2024.
Erectile dysfunction is a type of sexual dysfunction characterized by the inability to develop or maintain an erection of the penis during sexual activity. It is caused due to several physical and psychological issues such as stress, hypertension, heart disease, obesity and surgeries or injuries that affect the pelvic area or spinal cord. These drugs work by relaxing smooth muscle cells to improve the flow of blood into the penis by making the erections easier to get and maintain. They are a safe and effective way to cure erectile dysfunction. The most commonly used erectile dysfunction drugs are Viagra, Stendra, Cialis and Levitra.
The rise in aging population contributes to the growth of erectile dysfunction drugs market. Epidemiological studies consistently show that the prevalence of erectile dysfunction increases with aging. Erectile dysfunction affects as many as 20 million American men. Nonetheless, younger men are also suffering from erectile dysfunction owing to lifestyle choices such as smoking, overuse of alcohol, poor diet, and lack of physical activity. In addition, the increase in the number of men suffering from metabolic and cardiovascular diseases drives the growth of the erectile dysfunctional drug market. Nearly 133 million Americans suffer from at least one chronic disease, and the number is growing. Other organic causes of impotence in men include neurological problems, hormonal insufficiencies, and drug side effects. However, erectile dysfunction drugs can be dangerous when combined with other medications. Erectile dysfunction drugs cause side effects such as a headache, muscle aches, heartburn, diarrhea, visual changes, hearing loss, nasal congestion, and long-lasting erection in men curtails the growth of erectile dysfunction drugs market. Furthermore, increasing awareness about cures for erectile dysfunction and the emergence of generic drugs and new drug delivery techniques will create additional growth opportunities for the growth of the erectile dysfunction drug market. Moreover, the expiry of patents of several erectile dysfunction drugs is also projected to drive the growth of this market over the forecast period.
Among the geographies, North America holds the maximum market share in the erectile dysfunction drug market. The rising prevalence of erectile dysfunction among men in the North America region owing to the sedentary lifestyle and growing awareness the treatment methods for curing erectile dysfunction drives the growth of erectile dysfunction drug market in this region. Europe is the second largest region owing to the increasing incidences of cardiac diseases in this region. Asia-Pacific is the fastest growing in the erectile dysfunction drug market. The rise in the aging population in the Asia Pacific region drives the growth of erectile dysfunction drug market in this region.
The report on global erectile dysfunction drugs market covers segments such as a drug, mode of administration, and end-user. On the basis of a drug, the sub-markets include sildenafil (Viagra), tadalafil (Cialis), vardenafil (Levitra, Staxyn), avanafil (Stendra), muse suppository (alprostadil), and others. On the basis of mode of administration, the sub-markets include oral, topical, injections, and others. On the basis of end-user, the sub-markets include hospital pharmacies, retail pharmacies, and online pharmacies.
The report provides regional analysis covering geographies such as North America, Europe, Asia-Pacific, and Rest of the World. In this section, the key trends and market size for each geography are provided over the period of 2016-2024. The countries covered in the North America region include the U.S., Canada, and Mexico; while Asia-Pacific includes China, Japan, India, South Korea, Malaysia, and among others. Moreover, Germany, U.K., France, Spain, and Rest of Europe are included in the European region. The U.S. drives the growth in the North America region as it is the largest market in this region. The Asia-pacific region offers a substantial potential for the market growth owing to rapid growth in markets such as India and China.
The report provides profiles of the companies in the market such as Pfizer Inc., Bayer AG, Eli Lily & Co., DONG–A PHARM, Apricus Biosciences Inc., Vivus, Inc., Meda AB, SK Chemicals, Cristalia Produtos Quimicos Farmaceuticos Ltda., and Teva Pharmaceutical Industries Ltd.
The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of erectile dysfunction drugs market. Moreover, the study highlights current market trends and provides forecast from 2018-2024. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.
Get free analyst support for the queries before and post purchasing report.
Be assured of 100% customer satisfaction about the research and get 24X7 customer support.
Infinium has achieved over 400%+ growth in its repository and revenue over the last 2 years. Yes, we are proud to say we are growing at a great pace and becoming a trusted partner among our clients.
sign up for our newsletter